Bibliography
- Yuan C, Papagallo M. Handbook of opioid bowel syndrome. The Haworth Press, Inc.; 2005
- Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician 2007;10:479-91
- Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;20:649-71
- Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on us in opioid-related constipation. J Pain Symptom Manage 2002;24(1):71-90
- Culpepper-Morgan J, Inturrisi CE, Portenoy RK, Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992;52:90-5
- Hawkes ND, Richardson C, Evans BK, Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther 2001;15:625-30
- Jurna I, Baldauf J. Retardiert freigesetztes Naloxon oral: aufhebung der obstipation durch orales morphin ohne beseitigung der analgesie. Der Schmerz 1993;7:314-21
- Latasch L, Zimmermann M, Eberhardt B, Jurna I. Aufhebung einer Morphin-induzierten obstipation durch orales naloxone. Anaesthesist 1997;46:191-4
- Meissner W, Schmidt U, Hartmann M, Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9
- Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44
- Wilding IR, Richards JC, Whipps C, Monteith D. Pharmacoscintigraphic evaluation of a new “once-a-day” morphine preparation. Poster session presented at: gastrointestinal transport poster session. American Association of Pharmaceutical Scientists Annual Meeting; San Francisco, CA; 1998
- European medicines agency, International conference on harmonization-world health organization. Guideline for good clinical practice [EMA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. Available from: http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf [Last accessed 20 April 2010]
- World medical association declaration of helsinki: ethical principles for medical research involving human subjects [WMA Web site]. Ferney-Voltaire, France: WMA; 1989. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. [Last accessed 20 April 2010]
- McDermott JC, Scholes PD, Connor AL. Radiolabelling Technologies for Scintigraphic Evaluation of Oral Pharmaceutical Dosage Forms. Poster session presented at: Oral Controlled Release systems Poster Session. American Association of Pharmaceutical Scientists Annual Meeting; Atlanta, GA
- Krevsky B, Maurer AH, Niewiarowski T, Cohen S. Effect of verapamil on human intestinal transit. Dig Dis Sci 1992;37:919-24
- Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990;46:673-87
- Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92
- Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
- Vondrackova D, Leyendecker P, Meissner W, Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
- Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
- Sandner-Kiesling A, Leyendecker P, Hopp M, Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74